<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708901</url>
  </required_header>
  <id_info>
    <org_study_id>GR-2011-02348280</org_study_id>
    <nct_id>NCT02708901</nct_id>
  </id_info>
  <brief_title>Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters</brief_title>
  <official_title>Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Fondazione Stella Maris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto di Fisiologia Clinica CNR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Fondazione Stella Maris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of a 6-months supplementation with
      probiotic Vivomixx® on inflammatory and gastrointestinal (GI) biomarkers, gastrointestinal
      disturbances, behavioral and developmental profiles, and neurophysiological features in
      preschoolers with Autism Spectrum Disorders (ASD) with or without GI symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autism Spectrum Disorders (ASD) are most likely multifactorial diseases in which the
      combination of genetic and environmental factors might have a role in the expression of the
      phenotype. A high incidence of gastrointestinal (GI) symptoms is reported in ASD. GI
      disturbances and altered gut microflora could make a child with a genetic predisposition for
      ASD more prone to express the ASD phenotype or increase the severity of his behavioral
      symptoms. The exploitation of strategies which can reduce the gut production and absorption
      of toxins or restore normal gut microbiota, such as probiotics may represent a
      non-pharmacological option in the treatment of GI disturbances in ASD. The aim of this study
      is to determine effects of probiotics supplementation with Vivomixx® in ASD children on
      specific GI symptoms, ASD core deficits, cognitive and language development, on inflammatory
      and gastrointestinal (GI) biomarkers and on Quantitative Electroencephalographic measures
      (QEEG). Vivomixx® is a probiotic mixture of 8 probiotic strains (Bifidobacterium breve,
      Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus
      plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus).
      An additional aim of the study is to determine the environmental exposure to phthalates
      (chemical pollutant) in ASD children, and the possible effects of probiotic supplementation
      on their urinary concentrations. A group of 100 unselected preschoolers with ASD will be
      classified as belonging to the Gastro Intestinal (GI) group or to the Not Gastro Intestinal
      (NGI) group on the basis of the presence of significant GI symptoms at GI severity Index.
      Subjects belonging to the two groups (GI and NGI) will be blind randomized 1:1 to regular
      diet with probiotic Vivomixx® or with placebo for 6 months. All the participants will be
      assessed at the baseline, after three months and after six months from the baseline in order
      to evaluate the possible changes in GI symptoms, in ASD symptomatology, in other affective
      and behavioral comorbid symptoms, in plasmatic, urinary and fecal biomarkers related to
      abnormal intestinal function and in the electrophysiological patterns. The effects of
      treatments with probiotics on children with ASD need to be confirmed by rigorous controlled
      trials. Aiming to examine the impact of this treatment not only on clinical but also on
      neurophysiological patterns this trial sets out to provide new insights into the gut-brain
      connection in autism. Moreover, this study's results could add new data on the relationship
      between the presence of phthalates, clinical features and neurophysiological patterns in ASD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double blind study of dietary supplement compared to placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in severity level of ASD symptomatology</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of scores at Autism Diagnostic Observation Schedule-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in GI symptomatology</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at GI Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Electroencephalogram (EEG) power</measure>
    <time_frame>6 months</time_frame>
    <description>Registration with a 128-channels digital EEG: power will be assessed within each frequency band</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EEG coherence</measure>
    <time_frame>6 months</time_frame>
    <description>Registration with a 128-channels digital EEG: coherence will be assessed within each frequency band</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EEG asymmetry</measure>
    <time_frame>6 months</time_frame>
    <description>Registration with a 128-channels digital EEG: asymmetry will be assessed within each frequency band</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of serum Lipopolysaccharide</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of values of serum Lipopolysaccharide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of serum Leptin</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of values of serum Leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of serum Resistin</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of values of serum Resistin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of serum Tumor Necrosis Factor - alfa</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of values of serum Tumor Necrosis Factor - alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of serum Interleukin-6 (IL-6)</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of values of serum Interleukin-6 (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of serum Plasminogen Activator Inhibitor-1 (PAI-1)</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of values of serum Plasminogen Activator Inhibitor-1 (PAI-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of fecal calprotectin</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of values of fecal calprotectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in global ASD symptomatology assessed by Childhood Autism Rating Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of scores at Childhood Autism Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ASD symptomatology: repetitive behaviors</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at Repetitive Behavior Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ASD symptomatology: sensory profiles</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at Sensory Profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in global ASD symptomatology assessed by Social Communication Questionnaire</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at Social Communication Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Developmental Quotient</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of score at Griffiths Mental Developmental Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Adaptive Functioning</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of scores at Vineland Adaptive Behavior Scale-II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Behavioral Profiles</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at Child Behavior Checklist 1.5-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Parental Stress</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at Parenting Stress Index</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>GI Vivomixx®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 children with GI symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 children with GI symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGI Vivomixx®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 children without GI symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGI placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 children without GI symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vivomixx®</intervention_name>
    <description>Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months</description>
    <arm_group_label>GI Vivomixx®</arm_group_label>
    <arm_group_label>NGI Vivomixx®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months</description>
    <arm_group_label>GI Placebo</arm_group_label>
    <arm_group_label>NGI placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age-range: 18-72 months

          -  ASD diagnosis according to Diagnostic and Statistical Manual of Mental Disorders-5
             (DSM-5) criteria

        Exclusion Criteria:

          -  brain anomalies detected by Magnetic Resonance Imaging (MRI)

          -  neurological syndromes or focal neurological signs

          -  anamnesis of birth asphyxia, severe premature birth (≤ 28 gestational weeks) or
             perinatal injuries

          -  epilepsy

          -  significant sensory impairment

          -  diagnosis of organic GI Disorder (i.e. gastroesophageal reflux, food allergies,
             Inflammatory Bowel Disease)

          -  diagnosis of Coeliac Disease

          -  special diet (i.e. gluten-free diet, casein-free diet, high-protein diet, ketogenic
             diet)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>72 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa Santocchi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Stella Maris Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Santocchi, MD, PhD</last_name>
    <phone>+39 050 886111-313</phone>
    <email>e.santocchi@fsm.unipi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Letizia Guiducci, PhD</last_name>
    <phone>+39 050 3153147</phone>
    <email>letizia.guiducci@ifc.cnr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Stella Maris Foundation</name>
      <address>
        <city>Calambrone</city>
        <state>Pisa</state>
        <zip>56128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Santocchi, MD, PhD</last_name>
      <phone>+39 050 886313-111</phone>
      <email>e.santocchi@fsm.unipi.it</email>
    </contact>
    <contact_backup>
      <last_name>Letizia Guiducci, PhD</last_name>
      <phone>+39 050 3153147</phone>
      <email>letizia.guiducci@ifc.cnr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Elisa Santocchi, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Letizia Guiducci, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Fulceri F, Morelli M, Santocchi E, Cena H, Del Bianco T, Narzisi A, Calderoni S, Muratori F. Gastrointestinal symptoms and behavioral problems in preschoolers with Autism Spectrum Disorder. Dig Liver Dis. 2016 Mar;48(3):248-54. doi: 10.1016/j.dld.2015.11.026. Epub 2015 Dec 11.</citation>
    <PMID>26748423</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Probiotic Vivomixx®</keyword>
  <keyword>Gastrointestinal Symptoms</keyword>
  <keyword>Gut-Brain Axis</keyword>
  <keyword>Endophenotypes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

